Aimia has completed a valuation
Aimia has completed a valuation in connection with a substantial issuer bid, purchasing for cancellation CAD$150 million of shares.
Listed on the TSX, Aimia offers loyalty solutions for many of the world’s leading brands in the retail, consumer packaged goods, travel and hospitality, and financial services verticals.
Oaklins’ team in Canada was retained as a valuation expert by Aimia’s Audit Committee of the Board of Directors to provide an independent valuation in accordance with MI 61–101, and valued the common shares in the range of CAD$541–CAD$686 million.
Contacter l'équipe de la transaction
Transactions connexes
Niscon Inc. a été acquise par SGPS ShowRig.
Niscon Inc. a été acquise avec succès par SGPS ShowRig, un fournisseur mondial de solutions de scène, de levage et d’automatisation pour le divertissement en direct. Cette acquisition renforce l’engagement de SGPS ShowRig à repousser les limites de l’innovation dans l’industrie du divertissement. En intégrant la technologie unique de contrôle de mouvement de Niscon à son portefeuille, SGPS ShowRig renforce sa capacité à offrir des solutions de pointe, précises et innovantes.
En apprendre plusFairfest Media has acquired WTE Miami
Fairfest Media, organizer of OTM, the leading travel show in Asia, has acquired WTE Miami, the fastest-growing travel trade show in the USA. The acquisition marks a significant milestone in Fairfest’s global expansion, strengthening its presence in the Americas and beyond by leveraging decades of experience and leadership in Asia and India.
En apprendre plusBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
En apprendre plus